Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne zoonotic disease caused by CCHF virus and characterized by initial fever, headache, and malaise followed by gastrointestinal symptoms and, in severe cases, bleeding, shock, and multi-organ system failure.
Features include very common findings: Low platelet count (thrombocytopenia), Fever, Increased circulating IgM level, and Capillary leak; and common findings: Epistaxis, Diarrhea, Nausea and vomiting, and Abdominal pain and others. 78 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 10 | Diarrhea, Nausea and vomiting, Abdominal pain |
Biomarker and diagnostic research for Crimean-Congo hemorrhagic fever has been reported in the published literature.
Phenotype severity distribution: 4 very common features, 17 common features.
Estimated prevalence: Unknown (Unknown prevalence).
5 clinical trials registered, 3 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and biologic therapy. Pipeline includes 1 PHASE2, 2 PHASE1, 2 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06859619](https://clinicaltrials.gov/study/NCT06859619) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 12:06 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Crimean-Congo hemorrhagic fever
Blood and immune system |
7 |
Low platelet count (thrombocytopenia), Gingival bleeding, Enlarged spleen (splenomegaly) |
Heart and blood vessels | 7 | Hypertension, Tachycardia, Bradycardia |
Brain and nerves | 6 | Headache, Nervous system problems (abnormality of the nervous system), Emotional lability |
Lab test results | 3 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration), Increased circulating IgG concentration, Elevated LDH (tissue damage marker) (increased circulating lactate dehydrogenase concentration) |
Eyes | 3 | Ocular pain, Conjunctivitis, Retinal hemorrhage |
Skin | 3 | Excessive sweating (hyperhidrosis), Erythema nodosum, Morbilliform rash |
Muscles | 2 | Myalgia, Fasciculations |
Kidneys and urinary system | 2 | Blood in the urine (hematuria), Protein in the urine (proteinuria) |
Metabolism | 1 | Fever |
Ears | 1 | Vertigo |
Hormones | 1 | Adrenal insufficiency |
Lungs and breathing | 1 | High blood pressure in lung arteries (pulmonary arterial hypertension) |
Bones and joints | 1 | Arthralgia |
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases |
NA |
University Hospital, Montpellier |
NOT_YET_RECRUITING |
[NCT06624787](https://clinicaltrials.gov/study/NCT06624787) | Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care | NA | Liverpool School of Tropical Medicine | RECRUITING |
[NCT06684431](https://clinicaltrials.gov/study/NCT06684431) | Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic Fever | PHASE1 | Karolinska Institutet | UNKNOWN |
[NCT06799013](https://clinicaltrials.gov/study/NCT06799013) | Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever | PHASE1 | HDT Bio | RECRUITING |
[NCT06860334](https://clinicaltrials.gov/study/NCT06860334) | UMIT-2 - Adaptive Phase IIb Platform Trial to Determine the Efficacy and Safety of Therapeutics for CCHF | PHASE2 | Liverpool School of Tropical Medicine | RECRUITING |
220 publications have been identified in PubMed for Crimean-Congo hemorrhagic fever. Research spans Epidemiology / Natural History (36%), Basic Science / Preclinical (20%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 80 | 36% |
Laboratory research | 45 | 20% |
Research summaries | 30 | 14% |
Testing and diagnosis research | 21 | 10% |
Patient case studies | 19 | 9% |
New treatment approaches | 18 | 8% |
Clinical study results | 5 | 2% |
Other research | 2 | 1% |
Manucharyan A (2026). [PMID: 42081270](https://pubmed.ncbi.nlm.nih.gov/42081270/). *Vector Borne Zoonotic Dis*. [Basic Science / Preclinical]
Azami H (2026). [PMID: 41699955](https://pubmed.ncbi.nlm.nih.gov/41699955/). *Int J Environ Health Res*. [Epidemiology / Natural History]
Cakmak Taskin E (2026). [PMID: 42093144](https://pubmed.ncbi.nlm.nih.gov/42093144/). *Vector Borne Zoonotic Dis*. [Epidemiology / Natural History]
Shamamba SM (2026). [PMID: 41869298](https://pubmed.ncbi.nlm.nih.gov/41869298/). *Front Immunol*. [Review / Meta-Analysis]
Turgut I (2026). [PMID: 41186712](https://pubmed.ncbi.nlm.nih.gov/41186712/). *Abdom Radiol (NY)*. [Diagnostic / Biomarker]
Wupori K (2026). [PMID: 41754561](https://pubmed.ncbi.nlm.nih.gov/41754561/). *Viruses*. [Review / Meta-Analysis]
Jiang D (2026). [PMID: 41859109](https://pubmed.ncbi.nlm.nih.gov/41859109/). *Front Immunol*. [Clinical Trial Publication]
Kodama C (2026). [PMID: 41629835](https://pubmed.ncbi.nlm.nih.gov/41629835/). *BMC Infect Dis*. [Case Report / Case Series]
Saito T (2026). [PMID: 42037406](https://pubmed.ncbi.nlm.nih.gov/42037406/). *J Virol*. [Basic Science / Preclinical]
Beato-Benítez A (2026). [PMID: 41232226](https://pubmed.ncbi.nlm.nih.gov/41232226/). *Vet Microbiol*. [Epidemiology / Natural History]